Stephens Inc. AR Sells 265 Shares of Thermo Fisher Scientific Inc. $TMO

Stephens Inc. AR decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,204 shares of the medical research company’s stock after selling 265 shares during the period. Stephens Inc. AR’s holdings in Thermo Fisher Scientific were worth $10,625,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in TMO. Nuveen LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter worth about $532,360,000. EdgePoint Investment Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth about $172,139,000. Cohen Investment Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 6,655.5% in the first quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company’s stock worth $167,271,000 after buying an additional 331,180 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after buying an additional 329,974 shares in the last quarter. Finally, Auto Owners Insurance Co lifted its position in shares of Thermo Fisher Scientific by 6,773.5% in the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock worth $143,309,000 after buying an additional 283,810 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms recently commented on TMO. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, October 12th. HSBC reiterated a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research report on Thursday, July 24th. William Blair started coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating on the stock. Finally, Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective on the stock in a research report on Friday, July 11th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $589.10.

Thermo Fisher Scientific Trading Up 0.9%

Shares of NYSE TMO opened at $544.02 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The business’s 50 day moving average price is $497.37 and its 200-day moving average price is $449.73. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The company has a market cap of $205.43 billion, a price-to-earnings ratio of 31.46, a PEG ratio of 2.93 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the business posted $5.37 earnings per share. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.